MA53076A - Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique - Google Patents

Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique

Info

Publication number
MA53076A
MA53076A MA053076A MA53076A MA53076A MA 53076 A MA53076 A MA 53076A MA 053076 A MA053076 A MA 053076A MA 53076 A MA53076 A MA 53076A MA 53076 A MA53076 A MA 53076A
Authority
MA
Morocco
Prior art keywords
hydroxybenzoyl
glp
agonist
amino
salt
Prior art date
Application number
MA053076A
Other languages
English (en)
Other versions
MA53076B1 (fr
Inventor
Birgitte Nissen
Betty Lomstein Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA53076A publication Critical patent/MA53076A/fr
Publication of MA53076B1 publication Critical patent/MA53076B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA53076A 2018-02-02 2019-02-01 Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant MA53076B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154913 2018-02-02
PCT/EP2019/052487 WO2019149880A1 (fr) 2018-02-02 2019-02-01 Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique

Publications (2)

Publication Number Publication Date
MA53076A true MA53076A (fr) 2021-05-12
MA53076B1 MA53076B1 (fr) 2023-11-30

Family

ID=61157101

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53076A MA53076B1 (fr) 2018-02-02 2019-02-01 Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant

Country Status (24)

Country Link
US (2) US11833248B2 (fr)
EP (2) EP3746111B1 (fr)
JP (3) JP6898518B2 (fr)
KR (1) KR102647171B1 (fr)
CN (2) CN111683676B (fr)
AR (1) AR114353A1 (fr)
AU (1) AU2019216442A1 (fr)
BR (1) BR112020014624A2 (fr)
CA (1) CA3087928A1 (fr)
CL (1) CL2020001899A1 (fr)
CO (1) CO2020009997A2 (fr)
ES (1) ES2960687T3 (fr)
HR (1) HRP20231205T1 (fr)
HU (1) HUE063787T2 (fr)
IL (1) IL275778B2 (fr)
MA (1) MA53076B1 (fr)
MX (1) MX2020007598A (fr)
PE (1) PE20210453A1 (fr)
PH (1) PH12020551066A1 (fr)
PL (1) PL3746111T3 (fr)
RS (1) RS64643B1 (fr)
SG (1) SG11202006595RA (fr)
TW (1) TWI804571B (fr)
WO (1) WO2019149880A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
MY171146A (en) 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
JP2022545862A (ja) 2019-09-02 2022-11-01 ノヴォ ノルディスク アー／エス Ｇｌｐ－１ペプチドを含む錠剤を生成するためのプロセス
EP4142695A1 (fr) 2020-04-29 2023-03-08 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp-1 et de l'histidine
TWI801942B (zh) 2020-07-22 2023-05-11 丹麥商諾佛 儂迪克股份有限公司 適用於口服的glp-1及gip受體共促效劑
WO2022073151A1 (fr) * 2020-10-05 2022-04-14 Theracos Sub, Llc Formulations pharmaceutiques
JP7484018B2 (ja) 2020-11-06 2024-05-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１プロドラッグおよびその使用
JP7554928B2 (ja) 2020-12-18 2024-09-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１およびアミリン受容体の共作動薬
CN117642153A (zh) 2021-05-07 2024-03-01 伊莱利利公司 易蚀片剂
WO2023285580A1 (fr) * 2021-07-15 2023-01-19 Novo Nordisk A/S Comprimé comprenant un sel d'acide n-(8-(2-hydroxybenzoyl)amino) caprylique
US20230053812A1 (en) * 2021-07-27 2023-02-23 Aurobindo Pharma Ltd Stable peptide formulations for oral use
WO2023012263A1 (fr) 2021-08-04 2023-02-09 Novo Nordisk A/S Formulations solides de peptides oraux
WO2023065231A1 (fr) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Administration orale d'agents thérapeutiques
MX2024006492A (es) * 2021-12-01 2024-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica de doble agonista de los receptores glp-1 y gip y uso de la misma.
CN118613284A (zh) * 2021-12-11 2024-09-06 想象制药有限责任公司 用于口服给予的组合物和方法
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
EP4337244A1 (fr) * 2022-03-25 2024-03-20 Beijing QL Biopharmaceutical Co., Ltd. Compositions pharmaceutiques de conjugués polypeptidiques et leurs procédés d'utilisation
TW202346324A (zh) 2022-05-10 2023-12-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
TW202428309A (zh) 2022-12-22 2024-07-16 丹麥商諾佛 儂迪克股份有限公司 澱粉素受體促效劑
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US278923A (en) * 1883-06-05 Newspapee weappee
ES2059366T3 (es) 1986-03-12 1994-11-16 American Cyanamid Co Compuestos macrolidos.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995033474A1 (fr) 1994-06-03 1995-12-14 Tsumura & Co. Composition medicinale
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
ATE366584T1 (de) 1996-11-12 2007-08-15 Novo Nordisk As Verwendung von glp-1 peptiden
EP1015007A1 (fr) 1996-11-13 2000-07-05 The University Of Cincinnati Analogues de peptide yy et leurs utilisations
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (fr) 1997-09-16 2000-04-26 Smithkline Beecham Plc Polypeptide pancréatique
EP1056774A1 (fr) 1998-02-27 2000-12-06 Novo Nordisk A/S Derives de glp-1 tronques a l'extremite n-terminale
EP1056775B1 (fr) 1998-02-27 2010-04-28 Novo Nordisk A/S Derives de gpl-1 et de l'extendine au profil d'action etendu
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
EP1062240B1 (fr) 1998-02-27 2010-04-28 Novo Nordisk A/S Derives de glp-1 modifies a l'extremite n-terminale
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
PE20000564A1 (es) 1998-06-08 2000-07-05 Schering Corp Antagonistas receptores y5 de neuropeptidos
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1306091A3 (fr) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation de la prolifération des cellules de beta
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
CA2361716C (fr) 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Procede de preparation de salicylamides alkyles
WO2000048589A1 (fr) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Forme posologique orale solide contenant de l'heparine ou un heparinoide combinee a un support
ATE386508T1 (de) 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1175443A1 (fr) 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Exendines modifiees et agonistes de l'exendine
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CZ306180B6 (cs) 2000-12-07 2016-09-14 Eli Lilly And Company GLP-1 fúzní proteiny
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
CN1568195B (zh) 2000-12-14 2011-03-02 安米林药品公司 用于治疗代谢性疾病的肽yy及肽yy激动剂
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
WO2003026591A2 (fr) 2001-09-24 2003-04-03 Imperial College Innovations Ltd. Modification de comportement alimentaire
EP1461031B1 (fr) 2001-11-29 2016-06-29 Emisphere Technologies, Inc. Preparations pour une administration par voie orale d'acide cromoglycique
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1478347A1 (fr) 2002-02-01 2004-11-24 Pfizer Products Inc. Preparation d'azithromycine en granulat sec
NZ534125A (en) 2002-02-20 2006-11-30 Emisphere Tech Inc A formulation comprising a GLP-1 compound and a delivery agent
WO2004005342A1 (fr) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 et methodes de traitement du diabete
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP1583549A4 (fr) 2003-01-17 2006-10-04 Sod Conseils Rech Applic Analogues du peptide yy
WO2004067548A2 (fr) 2003-01-31 2004-08-12 Theratechnologies Inc. Metabolites chimiquement modifies de peptides regulateurs et methodes de production et d'utilisation associees
CA2518336A1 (fr) 2003-03-19 2004-11-04 Eli Lilly And Company Composes glp-1 a liaison polyethylene glycol
AU2004241242A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
EP1651248B1 (fr) 2003-07-11 2009-09-09 Novartis AG Compositions pharmaceutiques a dosage oral comprenant un agent d'apport sous forme micronisee
WO2005014035A2 (fr) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1667724A2 (fr) 2003-09-19 2006-06-14 Novo Nordisk A/S Nouvelles etiquettes d'affinite pour les proteines plasmiques
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
BRPI0417684A (pt) 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP1789440A4 (fr) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc Motifs de la famille de polypeptides pancreatiques et polypeptides les renfermant
WO2005077072A2 (fr) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes pouvant etre choisies
BRPI0508935A (pt) 2004-03-17 2007-09-25 7Tm Pharmas As agonistas de receptor seletivo y4 para intervenções terapêuticas
WO2005089790A2 (fr) 2004-03-17 2005-09-29 7Tm Pharma A/S Agonistes selectifs des recepteurs y2/y4 pour interventions therapeutiques
US20090186811A1 (en) 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
WO2005099672A1 (fr) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited Formulation pharmaceutique a liberation modifiee contenant de l'amoxicilline et du clavulanate
SG153039A1 (en) 2004-05-06 2009-06-29 Emisphere Tech Inc Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate
CA2564866A1 (fr) 2004-05-06 2005-11-17 Emisphere Technologies, Inc. Forme de dosage solide d'heparine mouillee
MXPA06013252A (es) 2004-05-14 2007-02-28 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (fr) 2004-06-02 2005-12-22 Abbott Laboratories Piperidines substituees a activite antiangiogenique
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
BRPI0512988A (pt) 2004-07-08 2008-04-22 Novo Nordisk As método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica
CN101443028A (zh) 2004-07-12 2009-05-27 爱密斯菲尔科技公司 用于递送肽yy和pyy激动剂的组合物
WO2006020207A2 (fr) 2004-07-19 2006-02-23 University Of Cincinnati Composes pour la regulation de l'appetit
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006049681A2 (fr) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Agonistes recepteur y2 neuropeptidiques selectifs
WO2006037810A2 (fr) 2004-10-07 2006-04-13 Novo Nordisk A/S Composes de glp-1 a action prolongee
EP1799711B1 (fr) 2004-10-07 2012-06-20 Novo Nordisk A/S Composes d'exendin-4 a action prolongee
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
JP5175553B2 (ja) 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
JP2008531059A (ja) 2005-03-04 2008-08-14 バイオレクシス ファーマシューティカル コーポレーション 改変トランスフェリン融合タンパク質
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2006097536A2 (fr) 2005-03-18 2006-09-21 Novo Nordisk A/S Agonistes a base de peptide dimere contre le recepteur de glp-1
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
WO2006097535A2 (fr) 2005-03-18 2006-09-21 Novo Nordisk A/S Agonistes de peptides de la famille du glucagone presentant une activite similaire a la secretine
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1863449A2 (fr) 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Absorption regulee de statines dans l'intestin
AU2006249869A1 (en) 2005-05-26 2006-11-30 Bristol-Myers Squibb Company N-terminally modified GLP-1 receptor modulators
CA2614619A1 (fr) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations permettant d'ameliorer l'administration par les muqueuses de pyy
US8975227B2 (en) 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
KR20080031414A (ko) 2005-07-18 2008-04-08 노보 노르디스크 에이/에스 비만치료에 사용하기 위한 신규 펩티드
PT2347762T (pt) 2005-08-19 2019-06-17 Amylin Pharmaceuticals Llc Exendina para o tratamento da diabetes e redução do peso corporal
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
BRPI0520566A2 (pt) 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y2 seletivos para intervenções terapêuticas
WO2007038942A1 (fr) 2005-09-21 2007-04-12 7Tm Pharma A/S Agonistes selectifs du recepteur y4 pour applications therapeutiques
WO2007061434A2 (fr) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. Formulation pharmaceutique de glp-1 et son utilisation pour traiter un syndrome metabolique
KR101432313B1 (ko) 2005-11-17 2014-08-20 노파르티스 아게 약제학적 조성물
ATE549350T1 (de) 2005-12-07 2012-03-15 Hoffmann La Roche Neuropeptid-2-rezeptor-agonisten
US20080318861A1 (en) 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
EP2526950A1 (fr) 2006-04-07 2012-11-28 Merrion Research III Limited Forme pharmaceutique solide par voie orale contenant un activateur
WO2007121318A2 (fr) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Préparations destinées à l'administration d'insuline
RU2451029C2 (ru) 2006-05-09 2012-05-20 Ново Нордиск А/С Производное инсулина
US20070292512A1 (en) 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
EP2040718B1 (fr) 2006-06-28 2017-12-27 Emisphere Technologies, Inc. Formulations de nitrate de gallium
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
WO2008023050A1 (fr) 2006-08-25 2008-02-28 Novo Nordisk A/S Composés d'exendine-4 acylée
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
JO2945B1 (en) 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
WO2008039351A2 (fr) 2006-09-22 2008-04-03 Novartis Ag Procédé de fabrication de comprimés contenant des agents de qualité pharmacologique
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
WO2008070547A1 (fr) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Formulations améliorées à base d'aciclovir
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
JP2010516652A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
CN101621991A (zh) 2007-03-02 2010-01-06 诺瓦提斯公司 降钙素的口服施用
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
WO2008154619A1 (fr) 2007-06-12 2008-12-18 Smithkline Beecham Corporation Procédés de détection de protéine dans le plasma
US20100279930A1 (en) 2007-07-09 2010-11-04 Stephen Robert Bloom Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
AU2008296444A1 (en) 2007-08-29 2009-03-12 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2187935A2 (fr) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Utilisation du peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe seul ou en combinaison avec le peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh en tant qu'agent thérapeutique
WO2009042922A2 (fr) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Conjugués inhibiteurs de peptide/peptidase et leurs procédés de fabrication et d'utilisation
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
AU2008318423B2 (en) 2007-11-02 2013-12-05 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EP2279204A1 (fr) 2008-05-16 2011-02-02 Novo Nordisk A/S Agonistes de récepteur y2 et/ou y4 à action longue
NZ591497A (en) 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
NZ592226A (en) 2008-10-15 2012-12-21 Bayer Cropscience Ag Use of dithiin tetracarboximides for treating phytopathogenic fungi for protecting plants
CA2741921A1 (fr) 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Agonistes du recepteur 2 de neuropeptide (y-2r) et leurs utilisations
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
EP2398492A4 (fr) 2009-02-20 2013-07-17 Ipsen Pharma Sas Conjugués cytotoxiques ayant un composé de liaison au récepteur de neuropeptide y
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
EP2477643A1 (fr) 2009-09-18 2012-07-25 Novo Nordisk A/S Agonistes du récepteur y2 à action prolongée
WO2011045232A2 (fr) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Agonistes du récepteur du neuropeptide-2 (y-2r)
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
JP2013514976A (ja) 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
EP2512518A1 (fr) 2009-12-16 2012-10-24 Novo Nordisk A/S Composés agonistes du récepteur glp 1 avec une extrémité n terminale modifiée
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (fr) 2010-03-05 2011-09-09 Conjuchem, Llc Méthodes d'administration de peptides insulinotropes
WO2011116139A2 (fr) 2010-03-16 2011-09-22 Chiasma Inc. Compositions pharmaceutiques améliorées et procédés d'administration
WO2011131646A1 (fr) 2010-04-20 2011-10-27 Novo Nordisk A/S Dérivés de gastrine à action prolongée
EP2565202A4 (fr) 2010-04-30 2013-10-30 Sanwa Kagaku Kenkyusho Co Peptide permettant d'améliorer la stabilité in vivo d'une substance physiologiquement active ou analogues et substance physiologiquement active et analogues présentant une amélioration de la stabilité in vivo
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
WO2013009545A1 (fr) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Polypeptides génétiquement modifiés ayant une durée d'action accrue avec une immunogénéicité réduite
DE102012102301B4 (de) 2012-03-19 2021-06-17 OSRAM Opto Semiconductors Gesellschaft mit beschränkter Haftung Optoelektronischer Halbleiterchip und Scheinwerfer mit einem solchen Halbleiterchip
EP4331667A3 (fr) 2012-03-22 2024-05-08 Novo Nordisk A/S Compositions comprenant un agent d'administration et leur préparation
MY171146A (en) * 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP2855517A1 (fr) 2012-05-29 2015-04-08 Novo Nordisk A/S Composés polypeptidiques pancréatiques et leur utilisation
EP2863895B1 (fr) * 2012-06-20 2021-04-14 Novo Nordisk A/S Composition de comprimé comprenant un peptide et un agent délivrant
US9764003B2 (en) 2012-07-01 2017-09-19 Novo Nordisk A/S Use of long-acting GLP-1 peptides
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
CA2910903A1 (fr) 2013-05-02 2014-11-06 Novo Nordisk A/S Dosage oral de composes glp-1
US10246497B2 (en) 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
CN105764919B (zh) 2013-11-15 2021-04-27 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
EP3129041B1 (fr) * 2014-04-07 2019-06-12 Novo Nordisk A/S Composés glp-1 acylés doubles
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
US20180263915A1 (en) * 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
WO2016128971A1 (fr) 2015-02-09 2016-08-18 Entera Bio Ltd. Traitement de fractures et défauts osseux
CA2988500A1 (fr) 2015-06-12 2016-12-15 Novo Nordisk A/S Composes pyy selectifs et leurs utilisations
EP3359181A1 (fr) 2015-10-07 2018-08-15 Cyprumed GmbH Formulations pharmaceutiques pour l'administration par voie orale de médicaments peptidiques
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CA3144611A1 (fr) * 2019-08-07 2021-02-11 Betty Lomstein PEDERSEN Compositions solides comprenant un agoniste de glp-1, un inhibiteur de sglt2 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique

Also Published As

Publication number Publication date
CN111683676B (zh) 2024-06-18
RU2020127262A (ru) 2022-02-14
AU2019216442A1 (en) 2020-08-20
BR112020014624A2 (pt) 2020-12-08
KR20200118435A (ko) 2020-10-15
EP3746111B1 (fr) 2023-07-19
EP4299118A2 (fr) 2024-01-03
PL3746111T3 (pl) 2024-01-15
US11833248B2 (en) 2023-12-05
JP2020529467A (ja) 2020-10-08
PH12020551066A1 (en) 2021-04-26
CN118662611A (zh) 2024-09-20
TW201945025A (zh) 2019-12-01
IL275778A (en) 2020-08-31
CA3087928A1 (fr) 2019-08-08
TWI804571B (zh) 2023-06-11
PE20210453A1 (es) 2021-03-08
SG11202006595RA (en) 2020-08-28
MA53076B1 (fr) 2023-11-30
HUE063787T2 (hu) 2024-01-28
US20200000728A1 (en) 2020-01-02
JP2021105014A (ja) 2021-07-26
IL275778B2 (en) 2023-12-01
IL275778B1 (en) 2023-08-01
JP6898518B2 (ja) 2021-07-07
HRP20231205T1 (hr) 2024-01-19
JP7494141B2 (ja) 2024-06-03
MX2020007598A (es) 2020-09-03
WO2019149880A1 (fr) 2019-08-08
CN111683676A (zh) 2020-09-18
RS64643B1 (sr) 2023-10-31
CL2020001899A1 (es) 2020-10-23
US20240099981A1 (en) 2024-03-28
EP4299118A3 (fr) 2024-04-10
KR102647171B1 (ko) 2024-03-15
AR114353A1 (es) 2020-08-26
ES2960687T3 (es) 2024-03-06
EP3746111A1 (fr) 2020-12-09
CO2020009997A2 (es) 2020-11-10
EP3746111C0 (fr) 2023-07-19
JP2024102371A (ja) 2024-07-30

Similar Documents

Publication Publication Date Title
MA53076A (fr) Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique
MA52556A (fr) Compositions solides comprenant un agoniste de glp-1 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique
EP4009957C0 (fr) Composition solide comportant un composé pyy et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate
MA51082A (fr) Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
IL277146A (en) Amino acid compounds and methods of use
IL289504A (en) Solid preparations that include a glp-1 agonist, an sglt2 inhibitor, and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid
MX2013006171A (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
BR112018076029A2 (pt) métodos e composições para conferir e/ou melhorar tolerância a herbicida com o uso de protoporfirinogênio oxidase ou variante do mesmo
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
MA46044A (fr) Compositions de nettoyage comprenant un acide aminé et leurs procédés d'utilisation
IL289505A (en) Solid preparations comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid
MX2022004718A (es) Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
NZ736818A (en) Benzoic acid herbicide composition
HRP20211574T1 (hr) Inhibitori il-8 za primjenu u liječenju određenih uroloških poremećaja
MA53119A (fr) Formulation thermostable d'insuline humaine a21g
GB201917723D0 (en) Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
IL309535A (en) A tablet containing a salt of N-(8-(2-hydroxybenzoyl)amino) caprylic acid
DK3989999T3 (da) Ny sammensætning indeholdende forgrenede aminosyrer
TH1901002056A (th) อะนาล็อกของคาร์บานิวคลีโอไซด์ที่ถูกแทนที่ด้วยระบบวงโมโนไซคลิกและไบไซคลิกชนิดใหม่สำหรับใช้เป็นตัวยับยั้งprmt5
HUE048850T2 (hu) Szilárd készítmények, amelyek tartalmaznak egy GLP-1 agonistát és az N-(8-(2-hidroxibenzoil)amino)kaprilsav egy sóját